$314 Million is the total value of Krensavage Asset Management, LLC's 14 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Buy | BIOGEN INC | $49,301,000 | +106.2% | 184,648 | +57.5% | 15.70% | +98.6% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $41,961,000 | -11.5% | 200,407 | -0.4% | 13.36% | -14.8% |
| REGN | Buy | REGENERON PHARMACEUTICALS | $41,945,000 | +17.5% | 60,889 | +0.8% | 13.36% | +13.2% |
| ALKS | Buy | ALKERMES PLC | $31,523,000 | -24.3% | 1,411,682 | +1.0% | 10.04% | -27.1% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $30,570,000 | +3.5% | 589,360 | -5.7% | 9.73% | -0.3% |
| Buy | EMBECTA CORP | $29,487,000 | +14.5% | 1,024,200 | +0.7% | 9.39% | +10.3% | |
| EXEL | Buy | EXELIXIS INC | $28,561,000 | -9.0% | 1,821,475 | +20.9% | 9.09% | -12.3% |
| CAH | Buy | CARDINAL HEALTH INC | $22,454,000 | +140.2% | 336,742 | +88.3% | 7.15% | +131.4% |
| TARO | Buy | TARO PHARMACEUTICAL INDUS | $17,412,000 | -17.1% | 580,793 | +0.0% | 5.54% | -20.1% |
| MCK | Sell | MCKESSON CORP | $10,846,000 | -59.9% | 31,913 | -61.5% | 3.45% | -61.4% |
| KOD | Sell | KODIAK SCIENCES INC | $3,633,000 | -14.2% | 469,388 | -15.3% | 1.16% | -17.4% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $3,199,000 | -40.5% | 121,083 | +0.1% | 1.02% | -42.7% |
| VNDA | New | VANDA PHARMACEUTICALS INC | $3,086,000 | – | 312,299 | +100.0% | 0.98% | – |
| NXTC | Buy | NEXTCURE INC | $86,000 | -41.1% | 31,298 | +1.0% | 0.03% | -43.8% |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -9,985 | -100.0% | -0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.